Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
absorb, Acino, ACTEMRA, alemtuzumab, Argentina, ARZERRA, Asia, attached, auto, banc, bankruptcy, BART, BBB, benchmark, Biotech, bowel, Brian, Cal, catch, chart, Chugai, circumstance, cladribine, competitor, Consent, conservative, corroborated, CV, declaratory, Deutschland, dispersion, EC, efalizumab, emergence, en, exemplary, EXTAVIA, Facet, FDIC, fifteen, fingolimod, franchise, FSPNo, graph, herewith, hierarchy, highest, highlighted, Hoechst, Hungary, ICC, immaterial, immunotherapy, incidence, inquiry, instability, invalid, invalidation, kroner, lastly, Lehman, lifecycle, LINGO, MAb, mediation, mistakenly, mondoGen, mortgage, MSCRG, nonrecurring, occupancy, override, par, parcel, physical, pivotal, Posner, pre, Progenitor, publish, published, Qualitative, RAPTIVA, recurring, rehearing, reorganization, revocation, revoked, RIXUTAN, roll, Sanofi, sense, slated, speak, split, spot, spring, spun, survey, swap, Tex, tightening, TLGP, tocilizumab, TREANDA, UK, ulcerative, unadjusted, unchanged, unobservable, upgraded, vi, waged, Weston, white, wrote, Zimmer
Removed:
acceleration, accepting, activated, added, Adelman, adhesion, administering, advanced, affiliated, AFFIRM, aggressive, al, ANDA, andRule, animal, announcement, anti, appeal, applicant, applying, argument, arrange, artificially, Authorisation, avoiding, Berlex, bioavailability, bioequivalence, bloodstream, bone, Boston, Brown, Burt, campaign, captioned, cascade, CDAI, choose, close, closely, collection, comparative, comparing, comprise, confirming, conspired, constrain, convey, copy, coupon, Creation, CRIPTO, decedent, declared, deduction, demanded, died, dilution, Dr, Dunn, earning, ENCORE, enhancing, enlarging, entitle, entrepreneurial, essential, evaluated, exchanged, expressed, Faheem, forfeited, formation, formulation, fulfilled, fusion, GAAP, gadolinium, governing, Grill, guarantor, Hasnain, Hillerod, Hybridon, hyperintense, identity, idle, immunomodulatory, indenture, induction, inflating, inhibit, inhibiting, insulation, internet, intervene, intervention, John, Judge, judged, Keller, Kellogg, leader, length, lieu, Lobel, lymphoproliferative, lymphotoxin, Lynch, MAA, Maine, mantle, marrow, McDermott, MDS, Merrill, migrating, migration, misleading, Nassau, negligence, neublastin, neuropathic, NIMO, noncompliance, notifying, observation, observational, observed, opposed, organ, outplacement, page, patchwork, peripheral, personal, personally, phototherapy, physiology, Pillsbury, pioneer, plaque, play, pleaded, power, precursor, predominantly, prevented, priced, principle, proceed, prohibited, promote, promulgated, proper, prospective, purported, purportedly, radioimmunotherapy, randomized, Rastetter, recommend, reconsidered, redeem, redemption, referenced, regenerate, rejection, relied, repatriate, repatriation, representation, rescue, restarted, retreatment, retrospective, role, salary, scan, seal, sensory, SENTINEL, seq, shorten, signaling, solicited, solid, soluble, sought, spanning, specificity, stem, steroid, Street, subordinated, substitute, suffering, thereunder, tissue, TMC, today, tolerated, trained, transfer, transformed, transitional, unrepatriated, unsealed, unspecified, USP, Washington, Winthrop
Filing tables
Filing exhibits
- 10-K Annual report
- 4.4 EX-4.4 Amendment No. 2 to Amended and Restated Rights Agreement Between Biogen Idec and Mellon Investor Services LLC Dated As of January 22, 2009.
- 10.19 EX-10.19 Amendment to Biogen Idec Inc. 2008 Omnibus Equity Plan Dated October 13, 2008
- 10.25 EX-10.25 Amendment to Biogen Idec Inc. 2006 Non-employee Directors Equity Plan Dated October 13, 2008
- 10.30 EX-10.30 Amendment to Biogen Idec Inc. 2005 Omnibus Equity Plan Dated October 13, 2008
- 10.34 EX-10.34 Amendment to Biogen Idec Inc. 2003 Omnibus Equity Plan Dated October 13, 2008
- 10.45 EX-10.45 Amendment to Biogen, Inc. 1985 Non-qualified Stock Option Plan Dated October 13, 2008
- 10.51 EX-10.51 Biogen Idec Inc. Executive Severance Policy - U.S. Executive Vice President, As Amended Effective October 13, 2008.
- 10.52 EX-10.52 Biogen Idec Inc. Executive Severance Policy - International Executive Vice President, As Amended Effective October 13, 2008.
- 10.53 EX-10.53 Biogen Idec Inc. Executive Severance Policy - U.S. Senior Vice President, As Amended Effective October 13, 2008.
- 10.54 EX-10.54 Biogen Idec Inc. Executive Severance Policy - International Senior Vice President, As Amended Effective October 13, 2008.
- 10.59 EX-10.59 Second Amendment to Employment Agreement Between Biogen Idec and James C. Mullen Dated As of December 4, 2008
- 10.61 EX-10.61 Employment Agreement Between Biogen Idec Management Services GMBH and Hans Peter Hasler Dated October 15, 2008.
- 10.63 EX-10.63 First Amendment to Employment Agreement Between Biogen Idec and Cecil B. Pickett Dated As of October 28, 2008
- 10.66 EX-10.66 First Amendment to Employment Agreement Between Biogen Idec and Craig E. Schneier Dated October 8, 2008
- 21.1 EX-21.1 Subsidiaries
- 23.1 EX-23.1 Consent of Pricewaterhousecoopers LLP - an Independent Registered Public Accounting Firm
- 31.1 EX-31.1 Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 31.2 EX-31.2 Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 32.1 EX-32.1 Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
BIIB similar filings
Filing view
External links
Exhibit 10.66
FIRST AMENDMENT TO
EMPLOYMENT AGREEMENT
EMPLOYMENT AGREEMENT
THIS AMENDMENT by and between BIOGEN IDEC INC., (the “Company”), and Craig Eric Schneier, Ph.D. (the “Executive”), dated as of September ___, 2008.
WHEREAS, the Executive and the Company are parties to an Employment Agreement dated as of October 8, 2001 (the “October 8, 2001 Agreement”); and
WHEREAS, the Executive and the Company desire to amend the October 8, 2001 Agreement as set forth herein.
NOW, THEREFORE, it is hereby agreed as follows:
1. | The following sentence is added to the first full paragraph of the October 8, 2001 Agreement |
“It is a condition of your employment with the Company that Jim Mullen will be President and Chief Executive Officer during your tenure with the Company.” |
2. | The paragraph relating to “Severance Benefits” is hereby amended and restated by the replacement in full with the following: |
“- Severance Benefits: You will be eligible for severance benefits pursuant to the U.S. Severance Plan for Executive Vice Presidents (the “Severance Plan”) on the terms and conditions provided therein; provided, however, that you will also be eligible for benefits thereunder in the event that you terminate your employment on account of a material breach of the provision in this letter in that Jim Mullen is no longer President and Chief Executive Officer of the Company. You will not be an employee of Biogen during the severance period and you will not accrue any benefits or other rights (such as, but not limited to, pension plan vesting or accrual, stock option vesting, vacation pay, etc.) during such period except health benefits as described in the “Severance Plan”. In addition to the severance benefits described above, the unforgiven amount of the Forgivable Loan referenced on the first page of this letter would be forgiven based on the definition of termination as noted herein.” |
Signed:
/s/ Craig Eric Schneier | 10/8/08 | |||||
/s/ Mike Thomas | 10/7/08 | |||||
Mike Thomas (on behalf of the Company) | Date |